Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies

SIMPLE SUMMARY: The association of venetoclax (VEN) with hypomethylating agents (HMAs) such as azacitidine (AZA) and decitabine (DECI) significantly improved the outcome of patients with newly diagnosed acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy. However, it is not...

Descripción completa

Detalles Bibliográficos
Autores principales: Ucciero, Andrealuna, Pagnoni, Federico, Scotti, Lorenza, Pisterna, Alessia, Barone-Adesi, Francesco, Gaidano, Gianluca, Patriarca, Andrea, Lunghi, Monia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526951/
https://www.ncbi.nlm.nih.gov/pubmed/37760587
http://dx.doi.org/10.3390/cancers15184618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526951/
https://www.ncbi.nlm.nih.gov/pubmed/37760587
http://dx.doi.org/10.3390/cancers15184618

Ejemplares similares